Shattuck Labs, Inc. (STTK) 股票分析

公司概述

Shattuck Labs, Inc. operates as a clinical-stage biotechnology enterprise dedicated to the development of antibodies designed to treat inflammatory and immune-mediated diseases within the United States market. The company functions specifically within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to capitalize on advancements in immunology and therapeutic antibody engineering. As of the latest reported data, the firm maintains a market capitalization of $530.58M, reports trailing twelve-month revenue of $1.00M, and employs approximately 40 individuals. These financial metrics and operational scale indicate that Shattuck Labs is a small-cap entity with limited current revenue generation relative to its market valuation, a profile typical for early-stage biotech firms that prioritize capital allocation toward research and development over immediate profitability. The disparity between the substantial market cap and minimal revenue suggests that the company's valuation is derived primarily from the potential clinical value of its pipeline assets, such as SL-325, rather than established commercial sales performance.

财务健康

The company reported revenue of $1.00M for the trailing twelve months, while net income stood at -$48,809,000 and EBITDA was -$47,739,000. The significant gap between the nominal revenue figure and the substantial net loss reveals a cost structure dominated by high research and development expenditures and clinical trial costs, which are standard for clinical-stage biotechnology companies but result in negative bottom-line performance. Free cash flow was recorded at -$21,513,876, indicating that the company is burning cash to fund its operations and pipeline advancement, which limits immediate financial flexibility but is often a strategic necessity for reaching Phase III trials or regulatory approval. When analyzing profitability margins, the gross margin is reported at -195.1%, the operating margin at -5142.7%, and the profit margin at 0.0%; these negative figures reflect the heavy upfront investment in drug discovery and manufacturing costs that exceed current sales revenue, a characteristic pattern for pre-commercialization pharmaceutical assets. On the balance sheet, the company holds cash of $78.06M against total debt of $2.42M, resulting in a debt-to-equity ratio of 2.94, which suggests a leveraged position relative to equity but provides a robust cash buffer to sustain operations without immediate refinancing risks. The current ratio stands at 11.70, a metric that indicates exceptionally strong short-term liquidity, implying the company possesses ample current assets to cover its short-term obligations many times over. Return on Equity is -60.3% and Return on Assets is -35.3%, metrics that reveal that management is currently generating negative returns on the capital deployed, a common feature in growth-stage biotechs where capital is consumed to build future value rather than generate current earnings.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, whereas the forward P/E is -14.70, implying that the market anticipates continued negative earnings in the near term. The price-to-book ratio is 5.39, indicating that the market values the company at more than five times its book value, which suggests a significant premium based on the potential future cash flows of its drug candidates rather than current tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 530.58 and the EV/EBITDA of -8.94 further highlight that traditional profitability-based multiples are not applicable, and the valuation relies heavily on pipeline potential and the specific clinical stage of assets like SL-325. The stock's 52-week trading range spans from a low of $0.71 to a high of $7.04, meaning the current price sits within a highly volatile band driven by clinical trial announcements and regulatory developments. With a beta of 1.29, the stock exhibits price volatility that is 29% higher than the broader market, reflecting the heightened risk and sensitivity of biotechnology equities to sector-specific news and market sentiment.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's status as a clinical-stage entity where historical growth rates are not yet established due to limited sales history. Since the company has not generated sufficient profits to sustain a dividend program, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all available cash to fund its research and development pipeline rather than distributing income to shareholders. Consequently, the company's strategy focuses on reinvesting earnings entirely into growth initiatives, such as advancing SL-325 through Phase I clinical trials, rather than providing income to investors. The overall growth and income profile is characterized by a complete reliance on capital markets for funding and a focus on long-term asset appreciation through successful clinical outcomes rather than short-term dividend yields or earnings expansion.